Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02900469 · ClinicalTrials.gov registry record · Early Phase 1
Presurgical Trial of Denosumab in Breast Cancer
A Early Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 44
- Enrollment target
NCT02900469 is a Early Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 44 participants.
The verdict
NCT02900469, a Early Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether one dose of denosumab can lead to changes in the tumor, which may decrease the ability of tumor to spread.
Interventions
- PROCEDURE Surgery
- BIOLOGICAL denosumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-10 |
| Est. Completion | 2020-01-03 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02900469
The ClinicalTrials.gov registry entry for NCT02900469 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgery is the first listed.
NCT02900469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02900469 about?
NCT02900469 is a clinical study titled "Presurgical Trial of Denosumab in Breast Cancer". The purpose of this study is to determine whether one dose of denosumab can lead to changes in the tumor, which may decrease the ability of tumor to spread.
What is the current status of trial NCT02900469?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 44 participants. The study started on 2016-10. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT02900469?
The interventions under investigation include: Surgery (PROCEDURE), denosumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02900469?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.